Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945989863> ?p ?o ?g. }
- W2945989863 endingPage "551" @default.
- W2945989863 startingPage "542" @default.
- W2945989863 abstract "This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, open-label comparator study to investigate the efficacy and safety of esaxerenone (CS-3150), a novel non-steroidal mineralocorticoid receptor blocker, in Japanese patients with essential hypertension. Eligible patients (n = 426) received esaxerenone (1.25, 2.5, or 5 mg/day), placebo, or eplerenone (50-100 mg/day) for 12 weeks. The primary efficacy endpoint was the change from baseline in sitting systolic and diastolic blood pressure (BP). Safety endpoints included adverse events and serum K+ elevation. There were significant dose-response reductions in the 2.5 and 5 mg/day esaxerenone groups for sitting BP (both p < 0.001) and 24-h BP (both p < 0.0001) compared with placebo, with a mean (95% confidence interval) change in sitting BP of -7.0 (-9.5 to -4.6)/-3.8 (-5.2 to -2.4) mmHg in the placebo group, and -10.7 (-13.2 to -8.2)/-5.0 (-6.4 to -3.6) mmHg, -14.3 (-16.8 to -11.9)/-7.6 (-9.1 to -6.2) mmHg, and -20.6 (-23.0 to -18.2)/ -10.4 (-11.8 to -9.0) mmHg for the 1.25, 2.5, and 5 mg/day esaxerenone groups, respectively, while the change was -17.4 (-19.9 to -15.0)/-8.5 (-9.9 to -7.1) mmHg for eplerenone. The incidence of adverse events was similar in all treatment groups. Serum K+ levels initially increased in proportion with esaxerenone dose but were stable from week 2 until week 12. Plasma esaxerenone concentration increased in proportion with the dose. In conclusion, esaxerenone is an effective and tolerable treatment option for patients with essential hypertension." @default.
- W2945989863 created "2019-05-29" @default.
- W2945989863 creator A5003990451 @default.
- W2945989863 creator A5021267745 @default.
- W2945989863 creator A5066495888 @default.
- W2945989863 creator A5077665206 @default.
- W2945989863 creator A5078329618 @default.
- W2945989863 date "2019-05-21" @default.
- W2945989863 modified "2023-09-25" @default.
- W2945989863 title "Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study" @default.
- W2945989863 cites W1968999388 @default.
- W2945989863 cites W1977014222 @default.
- W2945989863 cites W2013624937 @default.
- W2945989863 cites W2018109782 @default.
- W2945989863 cites W2064532153 @default.
- W2945989863 cites W2075460104 @default.
- W2945989863 cites W2089191146 @default.
- W2945989863 cites W2092791310 @default.
- W2945989863 cites W2098519186 @default.
- W2945989863 cites W2116965552 @default.
- W2945989863 cites W2123778248 @default.
- W2945989863 cites W2123825548 @default.
- W2945989863 cites W2125226019 @default.
- W2945989863 cites W2131805587 @default.
- W2945989863 cites W2141659719 @default.
- W2945989863 cites W2143954917 @default.
- W2945989863 cites W2159578092 @default.
- W2945989863 cites W2168712739 @default.
- W2945989863 cites W2173089390 @default.
- W2945989863 cites W2214627509 @default.
- W2945989863 cites W2275618507 @default.
- W2945989863 cites W2340395514 @default.
- W2945989863 cites W2404212513 @default.
- W2945989863 cites W2466427330 @default.
- W2945989863 cites W2793399999 @default.
- W2945989863 cites W2802617131 @default.
- W2945989863 cites W2888589263 @default.
- W2945989863 doi "https://doi.org/10.1038/s41371-019-0207-x" @default.
- W2945989863 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6760614" @default.
- W2945989863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31113987" @default.
- W2945989863 hasPublicationYear "2019" @default.
- W2945989863 type Work @default.
- W2945989863 sameAs 2945989863 @default.
- W2945989863 citedByCount "34" @default.
- W2945989863 countsByYear W29459898632019 @default.
- W2945989863 countsByYear W29459898632020 @default.
- W2945989863 countsByYear W29459898632021 @default.
- W2945989863 countsByYear W29459898632022 @default.
- W2945989863 countsByYear W29459898632023 @default.
- W2945989863 crossrefType "journal-article" @default.
- W2945989863 hasAuthorship W2945989863A5003990451 @default.
- W2945989863 hasAuthorship W2945989863A5021267745 @default.
- W2945989863 hasAuthorship W2945989863A5066495888 @default.
- W2945989863 hasAuthorship W2945989863A5077665206 @default.
- W2945989863 hasAuthorship W2945989863A5078329618 @default.
- W2945989863 hasBestOaLocation W29459898631 @default.
- W2945989863 hasConcept C126322002 @default.
- W2945989863 hasConcept C142724271 @default.
- W2945989863 hasConcept C168563851 @default.
- W2945989863 hasConcept C189135053 @default.
- W2945989863 hasConcept C197934379 @default.
- W2945989863 hasConcept C203092338 @default.
- W2945989863 hasConcept C204787440 @default.
- W2945989863 hasConcept C27081682 @default.
- W2945989863 hasConcept C2777097880 @default.
- W2945989863 hasConcept C2778525890 @default.
- W2945989863 hasConcept C2780072264 @default.
- W2945989863 hasConcept C71924100 @default.
- W2945989863 hasConcept C84393581 @default.
- W2945989863 hasConceptScore W2945989863C126322002 @default.
- W2945989863 hasConceptScore W2945989863C142724271 @default.
- W2945989863 hasConceptScore W2945989863C168563851 @default.
- W2945989863 hasConceptScore W2945989863C189135053 @default.
- W2945989863 hasConceptScore W2945989863C197934379 @default.
- W2945989863 hasConceptScore W2945989863C203092338 @default.
- W2945989863 hasConceptScore W2945989863C204787440 @default.
- W2945989863 hasConceptScore W2945989863C27081682 @default.
- W2945989863 hasConceptScore W2945989863C2777097880 @default.
- W2945989863 hasConceptScore W2945989863C2778525890 @default.
- W2945989863 hasConceptScore W2945989863C2780072264 @default.
- W2945989863 hasConceptScore W2945989863C71924100 @default.
- W2945989863 hasConceptScore W2945989863C84393581 @default.
- W2945989863 hasFunder F4320334790 @default.
- W2945989863 hasIssue "7" @default.
- W2945989863 hasLocation W29459898631 @default.
- W2945989863 hasLocation W29459898632 @default.
- W2945989863 hasLocation W29459898633 @default.
- W2945989863 hasLocation W29459898634 @default.
- W2945989863 hasOpenAccess W2945989863 @default.
- W2945989863 hasPrimaryLocation W29459898631 @default.
- W2945989863 hasRelatedWork W1947591645 @default.
- W2945989863 hasRelatedWork W1974142229 @default.
- W2945989863 hasRelatedWork W2559946394 @default.
- W2945989863 hasRelatedWork W2809017255 @default.
- W2945989863 hasRelatedWork W3113250085 @default.
- W2945989863 hasRelatedWork W3155195005 @default.
- W2945989863 hasRelatedWork W3172359983 @default.
- W2945989863 hasRelatedWork W3212096909 @default.